Literature DB >> 19253061

Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?

Erling Larsen1, Jan Blaakaer.   

Abstract

Worldwide, much effort is used every day to perform optimal surgery in the treatment of epithelial ovarian cancer. Treatment of ovarian cancer is a combination of surgery with optimal debulking followed by chemotherapy. However, the optimal timing of postoperative chemotherapy for ovarian cancer remains poorly defined. The literature is made up of seven studies performed in different ways and which have included varying prognostic factors. The general supposition is that the time interval (TI) does not have a prognostic influence but experimental studies have shown that it does affect the prognosis of the cancer. This commentary focuses on the importance of the TI between surgery and postoperative chemotherapy in this horrible disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19253061     DOI: 10.1080/00016340902814559

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.

Authors:  John K Chan; James J Java; Katherine Fuh; Bradley J Monk; Daniel S Kapp; Thomas Herzog; Jeffrey Bell; Robert Young
Journal:  Gynecol Oncol       Date:  2016-10-19       Impact factor: 5.482

2.  Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.

Authors:  Dong-Mei Fan; Hui-Rong Shi
Journal:  Int J Mol Sci       Date:  2011-11-29       Impact factor: 5.923

3.  A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin.

Authors:  Theodore J Brown; Taymaa May; Mitchell Clark; Alexandra Kollara
Journal:  J Ovarian Res       Date:  2021-11-16       Impact factor: 4.234

4.  Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.

Authors:  Soo Young Jeong; Chel Hun Choi; Tae Joong Kim; Jeong Won Lee; Byoung-Gie Kim; Duk Soo Bae; Yoo-Young Lee
Journal:  J Ovarian Res       Date:  2019-12-31       Impact factor: 4.234

5.  Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.

Authors:  Jun-Hyeok Kang; Yen-Ling Lai; Wen-Fang Cheng; Hyun-Soo Kim; Kuan-Ting Kuo; Yu-Li Chen; Yoo-Young Lee
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.379

6.  Survival and prognostic factors in women treated for epithelial ovarian cancer in western region of Saudi Arabia.

Authors:  Khalid H Sait; Mohammad Z Alam; Absarul Haque; Hesham K Sait; Maram K Sait; Nisreen M Anfinan
Journal:  Saudi Med J       Date:  2022-02       Impact factor: 1.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.